首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1271206

躁鬱症治療市場，各藥物類別，各流通管道，各地區-規模，佔有率，展望，機會分析，2023年～2030年

Bipolar Disorder treatment Market, By Drug Class, By Distribution Channel, And by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

出版日期: 2023年04月18日 | 出版商:

Coherent Market Insights | 英文 201 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

躁鬱症是一種終生疾病，可以透過適當的藥物治療來控制。用於控制躁鬱症症狀的藥物包括情緒穩定劑和非典型抗精神病藥。鋰與其他藥物等情緒穩定劑透過抑制躁狂和抑鬱等情緒波動來治療躁鬱症。患有躁鬱症的人會經歷異常強烈的情緒、不規律的睡眠模式、不規律的活動水準和情緒發作。躁鬱症是根據患者的症狀、家族史和生活史來診斷的。醫療保健提供者通常會進行心理健康評估以診斷躁鬱症。

市場上主要參與者日益採用合併、協議和合作等無機成長戰略，預計將推動預測期內的市場成長。

本報告對全球躁鬱症治療市場進行了深入分析，並提供了預測期(2023-2030年)的市場規模(百萬美元)和年複合成長率(CAGR%)，以 2022年為基準年。

Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Allergan plc.
Otsuka Holdings Co. Ltd.
Johnson & Johnson
Eli Lilly and Company
GlaxoSmithKline plc.
AstraZeneca Plc.
Novartis International AG
AbbVie Inc.
Lundbeck A/S
Minerva Neurosciences
Sumitomo Dainippon Pharma Co., Ltd.
Intra-Cellular Therapies Inc.
Gedeon Richter Plc.
Indivior PLC

第9章 Section

關於調查手法
關於出版社

簡介目錄

Product Code: CMI2605

Bipolar disorder is a lifelong disease, which can be managed with proper medication. The medications used to manage bipolar disorder symptoms include mood stabilizers and atypical antipsychotics. Mood stabilizers such as lithium and other drugs are used for the treatment of bipolar disorders by suppressing mood swings such as mania and depression. Cariprazine is an atypical antipsychotic drug indicated for the treatment of depressive episodes associated with bipolar I disorder in adults. Antidepressant medications are also prescribed to treat depressive episodes in bipolar disorder. Antidepressants combined with mood stabilizers are indicated to prevent the triggering of maniac episodes in patients with bipolar disorder. There is a sudden change in the mood of the patient and his/her ability to carry out daily tasks. There are four types of bipolar disorders: bipolar I, bipolar II, cyclothymic, and other specified and non-specified bipolar and related disorders. People suffering from bipolar disorder experience periods of unusually intense emotion, irregular sleep patterns, and activity levels, and mood episodes. Bipolar disorder is diagnosed based on the patient's symptoms, family history, and life history. The healthcare provider generally conducts a mental health evaluation for the diagnosis of bipolar disorder.

Market Dynamics

The increasing adoption of inorganic growth strategies such as mergers, agreements, and collaborations by key players operating in the market is expected to propel the market growth over the forecast period. For instance, in July 2019, Gedeon Richter plc, entered into an exclusive license agreement with Hikma Pharmaceuticals Plc. to commercialize cariprazine, a novel antipsychotic drug, in certain Middle East and North African or MENA markets. Moreover, earlier in August 2016, Gedeon RichterPlc. and Recordati signed an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic drug in Western Europe, Algeria, and Tunisia.

Key features of the study:

This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bipolar disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC
Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global infection surveillance market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market

Detailed Segmentation:

Global Bipolar Disorder Treatment Market, By Drug Class:
- Antipsychotics
- Antidepressants
- Mood Stabilizers
- Anti-anxiety Drugs and Others
Global Bipolar Disorder Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Bipolar Disorder Treatment Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region:
- South Africa
- Central Africa
- North Africa
Company Profiles
- Takeda Pharmaceutical Company Limited*
  - Company Highlights
  - Products Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer, Inc.
- Allergan plc
- Otsuka Holdings Co. Ltd.
- Johnson & Johnson
- Eli Lilly and Company
- GlaxoSmithKline plc
- AstraZeneca Plc
- Novartis International AG
- AbbVie Inc.
- Lundbeck A/S
- Minerva Neurosciences
- Sumitomo Dainippon Pharma Co., Ltd.
- Intra-Cellular Therapies Inc.
- Gedeon Richter Plc.
- Indivior PLC

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Key Highlights
Product Launch
Technological Advancements
PEST Analysis
Regulatory Scenario
Mergers and Acquisitions

4. Global Bipolar Disorder Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Bipolar Disorder Treatment Market, By Drug Class, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Mood Stabilizers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Anti-anxiety Drugs and Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Bipolar Disorder Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Bipolar Disorder Treatment Market, By Region, 2017 - 2030, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
U.S.
Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
North Africa
Central Africa
South Africa

8. Competitive Landscape

Takeda Pharmaceutical Company Limited *
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Allergan plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Otsuka Holdings Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
GlaxoSmithKline plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AstraZeneca Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis International AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Minerva Neurosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sumitomo Dainippon Pharma Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Intra-Cellular Therapies Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Gedeon Richter Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Indivior PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

9. Section

Research Methodology
About Us

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

全球雙相情感障礙市場（2022-2028）：按藥物類別（情緒穩定劑、抗驚厥藥）和類型（雙相 I 型障礙、雙相 II 型障礙）分列的規模、份額、增長分析和預測

FAQ

躁鬱症治療市場，各藥物類別，各流通管道，各地區-規模，佔有率，展望，機會分析，2023年～2030年

Bipolar Disorder treatment Market, By Drug Class, By Distribution Channel, And by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

目錄

第1章調查目的與前提條件

第2章市場展望

第3章市場動態，法規，趨勢分析

第4章躁鬱症治療的全球市場冠狀病毒(COVID-19)大流行造成的f的影響

第5章躁鬱症治療的全球市場，各藥物類別，2017年～2030年

第6章躁鬱症治療的全球市場，各流通管道，2017年～2030年

第7章躁鬱症治療的全球市場:各地區，2017年～2030年

第8章競爭情形

第9章 Section

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Bipolar Disorder Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

5. Global Bipolar Disorder Treatment Market, By Drug Class, 2017 - 2030, (US$ Million)

6. Global Bipolar Disorder Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

7. Global Bipolar Disorder Treatment Market, By Region, 2017 - 2030, (US$ Million)

8. Competitive Landscape

9. Section

躁鬱症治療市場，各藥物類別，各流通管道，各地區-規模，佔有率，展望，機會分析，2023年～2030年

Bipolar Disorder treatment Market, By Drug Class, By Distribution Channel, And by Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

目錄

第1章 調查目的與前提條件

第2章 市場展望

第3章 市場動態，法規，趨勢分析

第4章 躁鬱症治療的全球市場冠狀病毒(COVID-19)大流行造成的f的影響

第5章 躁鬱症治療的全球市場，各藥物類別，2017年～2030年

第6章 躁鬱症治療的全球市場，各流通管道，2017年～2030年

第7章 躁鬱症治療的全球市場:各地區，2017年～2030年

第8章 競爭情形

第9章 Section

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Bipolar Disorder Treatment Market- Impact of Coronavirus (Covid-19) Pandemic

5. Global Bipolar Disorder Treatment Market, By Drug Class, 2017 - 2030, (US$ Million)

6. Global Bipolar Disorder Treatment Market, By Distribution Channel, 2017 - 2030, (US$ Million)

7. Global Bipolar Disorder Treatment Market, By Region, 2017 - 2030, (US$ Million)

8. Competitive Landscape

9. Section

第1章調查目的與前提條件

第2章市場展望

第3章市場動態，法規，趨勢分析

第4章躁鬱症治療的全球市場冠狀病毒(COVID-19)大流行造成的f的影響

第5章躁鬱症治療的全球市場，各藥物類別，2017年～2030年

第6章躁鬱症治療的全球市場，各流通管道，2017年～2030年

第7章躁鬱症治療的全球市場:各地區，2017年～2030年

第8章競爭情形